Atea Pharmaceuticals, Inc. - common stock (AVIR) earnings
AVIR earnings moved a median of -2.63% by the close. Quarterly and annual AVIR reports and results, each read against the price at its own news timestamp. Back to the AVIR overview →
28 measured AVIR earnings events.
Where these AVIR earnings landedvs 26 measured AVIR earnings reactions
| Middle 50% of AVIR earnings reactions | -5.38% to +0.71% |
|---|---|
| Median reaction (to close) | -2.63% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 AVIR earnings events with a measured close landed between -5.38% and +0.71%; 31% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +3.65% | -2.69% | |
| Form 10-Q Atea Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +3.65% | -2.69% | |
| Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 | Press release | -0.21% | +0.85% | |
| Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -4.38% | -12.95% | |
| Form 10-Q Atea Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -4.38% | -12.95% | |
| Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 | Press release | +0.26% | -2.27% | |
| Form 10-K Atea Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +6.64% | +22.20% | |
| Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +2.50% | — | |
| Form 10-Q Atea Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +2.50% | — | |
| Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 | Press release | +0.70% | +1.25% | |
| Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -0.56% | -6.11% | |
| Form 10-Q Atea Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -0.56% | -6.11% | |
| Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 | Press release | -0.96% | -0.55% | |
| Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.86% | -9.31% | |
| Form 10-Q Atea Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.86% | -9.31% | |
| Form 10-K Atea Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +3.57% | +3.46% | |
| Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -1.72% | +0.29% | |
| Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 | Press release | -0.92% | -1.22% | |
| Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -0.61% | +6.71% | |
| Form 10-Q Atea Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -0.61% | +6.71% | |
| Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 | Press release | +0.00% | +1.06% | |
| Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +2.10% | -2.63% | |
| Form 10-Q Atea Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +2.10% | -2.63% | |
| Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 | Press release | -0.75% | -1.50% | |
| Form 10-K Atea Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.89% | -4.22% | |
| Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +1.11% | -5.38% | |
| Form 10-Q Atea Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +1.11% | -5.38% | |
| Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 | Press release | +0.77% | -4.64% |
Keep exploring
More AVIR: analyst actions → · SEC filings → · AVIR overview →